Related Experiment Video
Updated: Jul 29, 2026
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial
H R Black1, W J Elliott, J D Neaton
1Department of Preventive Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.
Controlled Clinical Trials
|July 31, 1998
Summary
The CONVINCE trial compared controlled onset-extended release verapamil to standard care for hypertension. It assessed major cardiovascular events in 15,000 patients over five years.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Hypertension management is crucial for reducing cardiovascular disease.
- Comparative effectiveness of different antihypertensive regimens requires investigation.
- Controlled Onset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial addresses this need.
Purpose of the Study:
- To compare the incidence of major adverse cardiovascular events between COER-verapamil and standard antihypertensive therapy.
- To evaluate secondary endpoints including cardiovascular-related hospitalizations, blood pressure control, and all-cause mortality.
Main Methods:
- A randomized, prospective, double-blind, parallel-group, actively controlled, multicenter international trial.
- 15,000 hypertensive patients aged 55+ with a second cardiovascular risk factor were enrolled.
- Treatment arms: COER-verapamil vs. standard care (hydrochlorothiazide or atenolol).
Main Results:
- Primary endpoint: fatal/nonfatal myocardial infarction, fatal/nonfatal stroke, or cardiovascular death.
- Secondary endpoints: cardiovascular hospitalizations, blood pressure control, time of event occurrence, all-cause mortality, cancer incidence, bleeding hospitalizations.
- Long-term outcomes and safety profiles of the two regimens were assessed.
Conclusions:
- The CONVINCE trial provides critical data on the comparative effectiveness and safety of COER-verapamil versus standard antihypertensive treatments.
- Findings will inform clinical practice guidelines for hypertension management.
- The study contributes to understanding long-term cardiovascular risk reduction strategies.
More Related Videos
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...